150 related articles for article (PubMed ID: 2314830)
1. Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen.
Imai S; Kiyozuka Y; Maeda H; Noda T; Hosick HL
Oncology; 1990; 47(2):177-84. PubMed ID: 2314830
[TBL] [Abstract][Full Text] [Related]
2. Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sekiya S; Takamizawa H; Suzuki N; Tokita H
Arch Gynecol Obstet; 1988; 243(2):69-81. PubMed ID: 3165255
[TBL] [Abstract][Full Text] [Related]
3. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
4. [Establishment and characterization of a human ovarian adenocarcinoma cell line OC-8611].
Huang JS
Zhonghua Zhong Liu Za Zhi; 1989 Nov; 11(6):416-8. PubMed ID: 2634538
[TBL] [Abstract][Full Text] [Related]
5. [Biological properties of two newly established cell lines (RMUG-S, RMUG-L) from a human ovarian mucinous cystadenocarcinoma].
Sakayori M; Nozawa S; Udagawa Y; Chin K; Lee SG; Sakuma T; Iizuka R; Wada Y; Yoshida S; Takeda Y
Hum Cell; 1990 Mar; 3(1):52-6. PubMed ID: 2083224
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-alpha promotes tumor markers secretion from human ovarian cancers in vitro.
Kurachi H; Adachi H; Morishige K; Adachi K; Takeda T; Homma H; Yamamoto T; Miyake A
Cancer; 1996 Sep; 78(5):1049-54. PubMed ID: 8780543
[TBL] [Abstract][Full Text] [Related]
7. Morphologic characteristics, proliferation, and tumor marker expression of two human ovarian carcinoma cell lines in three-dimensional culture.
Morimitsu Y; Yano H; Kojiro M
Gynecol Oncol; 1993 Feb; 48(2):155-64. PubMed ID: 8428685
[TBL] [Abstract][Full Text] [Related]
8. Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma.
Ishiwata I; Ishiwata C; Kobayashi N; Ishikawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1987 May; 39(5):831-6. PubMed ID: 3598277
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a cell line (OMC-3) originating from a human mucinous cystadenocarcinoma of the ovary.
Yamada T; Ueda M; Otsuki Y; Ueki M; Sugimoto O
Gynecol Oncol; 1991 Feb; 40(2):118-28. PubMed ID: 2010102
[TBL] [Abstract][Full Text] [Related]
10. A new human ovarian carcinoma cell line: establishment and analysis of tumor-associated markers.
Horowitz AT; Treves AJ; Voss R; Okon E; Fuks Z; Davidson L; Biran S
Oncology; 1985; 42(5):332-7. PubMed ID: 2412195
[TBL] [Abstract][Full Text] [Related]
11. Combined immunohistochemical study of tissue polypeptide antigen and cancer antigen 125 in human ovarian tumours.
Ghazizadeh M; Sasaki Y; Oguro T; Aihara K; Tenjin H; Araki T
Histopathology; 1990 Aug; 17(2):123-8. PubMed ID: 2227836
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma.
Negishi Y; Furukawa T; Oka T; Sakamoto M; Hirata T; Okabe K; Matayoshi K; Akiya K; Soma H
Gynecol Obstet Invest; 1987; 23(3):200-7. PubMed ID: 3474196
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a human ovarian carcinoma cell line: UCI 101.
Fuchtner C; Emma DA; Manetta A; Gamboa G; Bernstein R; Liao SY
Gynecol Oncol; 1993 Feb; 48(2):203-9. PubMed ID: 8428692
[TBL] [Abstract][Full Text] [Related]
14. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
15. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
Kataoka A; Yakushiji M
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
[TBL] [Abstract][Full Text] [Related]
16. Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo.
Ishiwata I; Ono I; Ishiwata C; Soma M; Nakaguchi T; Ohara K; Hirano M; Ishikawa H
Exp Pathol; 1991; 41(1):1-9. PubMed ID: 1850701
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a new human cell-line (AMOC-2) derived from a serous adenocarcinoma of ovary.
Yabushita H; Ueno N; Sawaguchi K; Higuchi K; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jul; 41(7):888-94. PubMed ID: 2794621
[TBL] [Abstract][Full Text] [Related]
18. Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression.
Molthoff CF; Calame JJ; Pinedo HM; Boven E
Int J Cancer; 1991 Jan; 47(1):72-9. PubMed ID: 1985883
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the CA125 antigen secreted from a newly established human ovarian cancer cell line (SHIN-3).
Imai S; Maeda H; Kiyozuka Y; Noda T; Moriyama I; Ichijo M
Acta Pathol Jpn; 1989 Jan; 39(1):43-9. PubMed ID: 2469292
[TBL] [Abstract][Full Text] [Related]
20. [Clinical usefulness of the combination assay of CA 125, SLX, and CA 72-4 in patients with ovarian cancer].
Kobayashi H; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1731-5. PubMed ID: 2574209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
